Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors

Table 4 Correlation between durvalumab and avelumab activity and outcome and programmed cell death protein ligand 1 immunohistochemestry score

Author/study	Marker antibody	Tumor type	Treatment line	PD-L1 cutoff	N pts	Response (%)	mPFS mo (95%CI)	mOS mo (95%CI)
Durvalumab
Gulley et al[24] Phase 1/2	Ventana SP263	NSCLC	1	≥ 25%	43	25
				< 5%	8	12
Avelumab
Verschraegen etal[25] Phase 1b	?	NSCLC	≥ 2	≥ 1%	118	14.40	11.7 wk	NR
				< 1%	20	10	5.9 wk	NR
Sheng et al[26] Javelin Phase Ib	?	NSCLC	1	≥ 1%	35	20	NR	NR
				< 1%	10	0	NR	NR

NR: Not reported; pts: Patients; NSCLC: Non-small cell lung cancer; PD-L1: Programmed cell death protein ligand 1; mPFS: Median progression free survival; mOS: Median overall survival.